Last reviewed · How we verify
Oral cefalexin only
At a glance
| Generic name | Oral cefalexin only |
|---|---|
| Sponsor | Murdoch Childrens Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Losartan on Cephalexin (PHASE1)
- Utility of Single-dose Oral Antibiotic Prophylaxis in Prevention of Surgical Site Infection in Dermatologic Surgery (PHASE4)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children (PHASE4)
- BonE and Joint Infections - Simplifying Treatment in Children Trial (PHASE4)
- A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) (PHASE3)
- The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral cefalexin only CI brief — competitive landscape report
- Oral cefalexin only updates RSS · CI watch RSS
- Murdoch Childrens Research Institute portfolio CI